Research programme: CMV-based malaria vaccines - Vir Biotechnology

Drug Profile

Research programme: CMV-based malaria vaccines - Vir Biotechnology

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Oregon Health & Science University; TomegaVax
  • Developer Oregon Health & Science University; Vir Biotechnology
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 09 Aug 2016 Preclinical trials in Malaria in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top